These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
353 related articles for article (PubMed ID: 24755886)
1. Trabectedin, a drug acting on both cancer cells and the tumour microenvironment. D'Incalci M; Badri N; Galmarini CM; Allavena P Br J Cancer; 2014 Aug; 111(4):646-50. PubMed ID: 24755886 [TBL] [Abstract][Full Text] [Related]
2. Biology of ovarian cancer and trabectedin mechanism of action. Ray-Coquard I Future Oncol; 2013 Dec; 9(12 Suppl):11-7. PubMed ID: 24195525 [TBL] [Abstract][Full Text] [Related]
3. The intriguing patterns of tumor response to trabectedin. Sanfilippo R; Casali PG Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):21-4. PubMed ID: 23638727 [TBL] [Abstract][Full Text] [Related]
4. Trabectedin for the treatment of breast cancer. D'Incalci M; Zambelli A Expert Opin Investig Drugs; 2016; 25(1):105-15. PubMed ID: 26592307 [TBL] [Abstract][Full Text] [Related]
10. A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma. Uboldi S; Calura E; Beltrame L; Fuso Nerini I; Marchini S; Cavalieri D; Erba E; Chiorino G; Ostano P; D'Angelo D; D'Incalci M; Romualdi C PLoS One; 2012; 7(4):e35423. PubMed ID: 22523595 [TBL] [Abstract][Full Text] [Related]
11. Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer. Carter NJ; Keam SJ Drugs; 2007; 67(15):2257-76. PubMed ID: 17927287 [TBL] [Abstract][Full Text] [Related]
12. Trabectedin--a targeted chemotherapy? von Mehren M Lancet Oncol; 2007 Jul; 8(7):565-7. PubMed ID: 17613417 [No Abstract] [Full Text] [Related]
13. Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer. Carter NJ; Keam SJ Drugs; 2010 Feb; 70(3):355-76. PubMed ID: 20166769 [TBL] [Abstract][Full Text] [Related]
14. [Trabectedin (ET-743/Yondelis) for treating soft tissue sarcomas and ovarian cancer]. Gennigens C; Jerusalem G Rev Med Liege; 2011; 66(7-8):452-5. PubMed ID: 21942081 [TBL] [Abstract][Full Text] [Related]
15. The efficacy of trabectedin in treating ovarian cancer. Teplinsky E; Herzog TJ Expert Opin Pharmacother; 2017 Feb; 18(3):313-323. PubMed ID: 28140689 [TBL] [Abstract][Full Text] [Related]
16. Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents. Uboldi S; Bernasconi S; Romano M; Marchini S; Fuso Nerini I; Damia G; Ganzinelli M; Marangon E; Sala F; Clivio L; Chiorino G; Di Giandomenico S; Rocchi M; Capozzi O; Margison GP; Watson AJ; Caccuri AM; Pastore A; Fossati A; Mantovani R; Grosso F; Tercero JC; Erba E; D'Incalci M Int J Cancer; 2012 Jul; 131(1):59-69. PubMed ID: 21805478 [TBL] [Abstract][Full Text] [Related]
18. The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma. Saponara M; Stacchiotti S; Gronchi A Expert Rev Anticancer Ther; 2016 May; 16(5):473-84. PubMed ID: 27043847 [TBL] [Abstract][Full Text] [Related]
19. Novel models of myxoid liposarcoma xenografts mimicking the biological and pharmacologic features of human tumors. Frapolli R; Tamborini E; Virdis E; Bello E; Tarantino E; Marchini S; Grosso F; Sanfilippo R; Gronchi A; Tercero JC; Peloso G; Casali P; Pilotti S; D'Incalci M Clin Cancer Res; 2010 Oct; 16(20):4958-67. PubMed ID: 20732964 [TBL] [Abstract][Full Text] [Related]
20. Trabectedin as a chemotherapy option for patients with BRCA deficiency. Monk BJ; Lorusso D; Italiano A; Kaye SB; Aracil M; Tanović A; D'Incalci M Cancer Treat Rev; 2016 Nov; 50():175-182. PubMed ID: 27710871 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]